For a researcher building a growth hormone axis protocol, CJC-1295 No DAC is rarely the only compound worth evaluating. Understanding where it sits relative to other GHRH analogs and GH secretagogues — and why researchers choose one over another — requires a clear look at mechanism, half-life profile, and what each compound brings to a defined experimental design.
CJC 1295 no dac alternatives is a search that typically comes from researchers either qualifying their first GHRH compound or expanding an existing protocol into adjacent receptor pathways. This post maps the relevant options in the current research catalog.
Understanding the GHRH Analog Research Class
Growth hormone-releasing hormone (GHRH) is the endogenous 44-amino acid peptide that drives GH secretion from the anterior pituitary. CJC-1295 No DAC — widely called Modified GRF 1-29 — is a synthetic analog of the first 29 residues of GHRH, with four amino acid substitutions that improve stability over the native sequence. It binds the GHRH receptor and produces a GH pulse with a physiological pulsatile profile.
The substitutions in CJC-1295 No DAC address a specific vulnerability in the native GRF sequence: cleavage by dipeptidyl peptidase IV (DPP-IV) at the Ala2 position. Native GRF 1-29 has a half-life measured in minutes because DPP-IV rapidly degrades it in circulation. The Ala2 to Aib substitution in CJC-1295 No DAC eliminates that cleavage site, extending functional half-life to approximately 30 minutes in preclinical models. That window is short enough to produce pulsatile GH release rather than sustained baseline elevation — a distinction that matters depending on what the protocol is trying to measure.
Our CJC-1295 No DAC comes in 5mg vials, synthesized to >99% purity in our US cGMP labs, with third-party COA documentation from Freedom Diagnostics and Horizon Analytical.
How CJC-1295 No DAC Compares to Adjacent Compounds
Ipamorelin operates through an entirely different receptor. Where CJC-1295 No DAC is a GHRH receptor agonist, ipamorelin is a GH secretagogue that acts through the ghrelin receptor (GHSR-1a). The two pathways are not redundant — they are complementary, and co-stimulation at both receptors produces synergistic GH output beyond what either compound achieves alone. Researchers who need to study the interaction between GHRH-R and GHSR-1a signaling, or who want to control GH output levels precisely in a model system, often maintain both compounds. Our ipamorelin is available in 5mg vials at the same purity specification. Because the two peptides have roughly matched half-lives, study designs that use both can be structured around coincident receptor stimulation without complex dosing staggering.
CJC-1295 with DAC is the long-acting variant. Drug Affinity Complex (DAC) technology covalently attaches the peptide to circulating albumin via a lysine side-chain linker, extending half-life from approximately 30 minutes to several days. This produces sustained GH elevation rather than pulsatile GH release. The distinction between pulsatile and tonic GH secretion is not a minor protocol preference — it represents mechanistically different physiological states. Researchers studying GH axis dynamics often maintain both variants to compare the two secretion profiles in parallel arms. Our CJC-1295 DAC is available in 2mg vials, given that DAC-form dosing is typically lower in molar terms due to the extended duration.
Sermorelin is the earlier generation of synthetic GHRH analog, based on the first 29 residues of native GHRH without the DPP-IV resistance substitutions present in CJC-1295 No DAC. Its half-life is substantially shorter and it is more rapidly cleared. Researchers using sermorelin as a reference compound for baseline GHRH-R activity — to establish a comparison point before testing the modified analog — find it useful precisely because its pharmacokinetic profile is well characterized in the published literature.
Choosing Based on Research Protocol Requirements
Selection between CJC-1295 No DAC and these alternatives generally resolves around three questions.
First: does the protocol need pulsatile GH release or sustained elevation? Pulsatile release correlates with physiological secretion patterns and suits protocols studying GH pulse dynamics. Sustained elevation produced by the DAC form may be more appropriate for protocols requiring a stable GH background.
Second: is the research question about GHRH receptor signaling specifically, or about GH output as an endpoint? A GHRH-only protocol isolates the GHRH-R pathway; a combined GHRH plus secretagogue protocol tests the integrated output of both receptors and suits different experimental questions.
Third: what is the study duration and administration schedule? Short acute studies can work with either form. Multi-week studies where dosing logistics are a variable may benefit from the extended duration of the DAC form.
The growth hormone axis research hub covers the foundational receptor biology and catalog positioning across GHRH analogs, secretagogues, and related compounds for researchers building a fuller picture of the growth hormone axis space.
FAQ
What is the difference between CJC-1295 No DAC and Modified GRF 1-29?
They are different names for the same compound. Both refer to the 29-residue GHRH analog with four amino acid substitutions — Ala2 to Aib, Asn8 to Gln, Gly15 to Ala, Leu27 to Ile — that improve resistance to DPP-IV cleavage and oxidative degradation. The naming difference is a convention artifact from how different manufacturers and researchers labeled the compound at different stages of its development. There is no chemical distinction.
Can CJC-1295 No DAC and CJC-1295 DAC be used in the same study design?
Researchers do run parallel arms using both variants to compare pulsatile versus sustained GH secretion profiles within the same experimental model. The compounds are chemically distinct — a DAC-conjugated peptide cannot be converted to the non-DAC form — so separate vials and separate study arms are required. Using both within a well-controlled design isolates the contribution of secretion pattern to downstream outcomes.
How does ipamorelin complement CJC-1295 No DAC in growth hormone research?
The two peptides bind distinct receptors: GHRH-R for CJC-1295 No DAC and GHSR-1a for ipamorelin. In GH release studies, dual-receptor stimulation amplifies GH output beyond what either compound achieves in isolation. Study designs that use both peptides allow researchers to dissect pathway-specific contributions or characterize the full magnitude of GH output under combined stimulation conditions.
All products discussed are for laboratory research use only and are not for human or veterinary use.